Stock Analiz

MediWound Ltd. MDWD

Medicinal Chemicals and Botanical Products · IPO 2014 · data as of November 13, 2026

$12.90Market cap $186M
Open the interactive analysis →

MediWound Ltd. (MDWD) is a healthcare company listed in the US with a market value of about $186M. In the twelve months to September 30, 2026 it had revenue of $10M and net income of -$24M, a net margin of -235.0%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -5% a year, a 5-year average ROIC of -48%.

About MediWound

MediWound is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2014. Revenue went from $601000 in 2015 to $17M in 2025, growth of about 39.7% a year. It was profitable in 1 of the last 10 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S18.6
P/B5.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-16.1%
Revenue growth (5 yrs, per year)-4.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-91.4%
ROIC (5-yr avg.)-48.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$10M$17M$20M$19M$26M$24M$22M$32M$3M$2M$2M
Net income-$24M-$24M-$30M-$7M-$20M-$14M-$9M$5M-$1M-$22M-$19M
Free cash flow—-$22M-$20M-$17M-$12M-$9M-$8M$7M-$13M-$18M-$17M
EPS (diluted)$-1.87$-1.66$-2.10$-0.47$-1.36$-0.94$-0.64$0.34$-0.07$-1.54$-1.31
Net margin-235.0%-140.8%-149.5%-35.9%-74.0%-57.0%-42.3%15.6%-31.1%-887.4%-1212.1%
ROIC—-45.8%-49.2%-38.2%-60.4%—-121.6%29.6%-34.9%-115.4%-204.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $29.67, 130% above the current price; targets range from $25.00 to $36.00; the consensus rating is “Strong buy”; expected EPS is $-2.02 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does MediWound pay a dividend?

Not currently.

Is MediWound a good stock to buy?

We do not give buy or sell advice. MediWound scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.